Uncovering global genetic diversity for equitable precision medicine
)
- Published on: July 1 2025
In this webinar, Francisco de la Vega (CTO, Galatea Bio) discusses the underrepresentation of global genetic diversity in current resources, especially for non-European and admixed populations, and how this hampers the discovery of new therapeutic targets.
He shares two studies – first on familial hypercholesterolemia in an admixed cohort, which uncovered novel genetic contributors to the disease and confirmed them with Oxford Nanopore long-read sequencing.
In the second, nanopore sequencing was used on a cohort of understudied African diaspora populations in the Americas (CAAPA), showing how this data can enrich variant catalogues, support clinical interpretation, and help drive more equitable precision medicine.
Please note:
This is independent, investigator-led research using Oxford Nanopore technology. Oxford Nanopore products are for research use only, and not for use in diagnostic procedures.
